FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT O STATEMENT O Filed pursu.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres  MIDDLETON		suer Name <b>and</b> Tic ereotaxis, Inc.			g Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
(Last)	(First)	(Middle)		3. Da	ate of Earliest Trans			h/Day/Year)		_	X Director Officer (give ti	tle O	% Owner her (specify llow)	
400 SOUTH EL	4. If .	Amendment, Date of	of Origin	nal File	ed (Month/Day		6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) SAN MATEO CA 94402-1708										X Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(State)	(Zip)							Person					
		Table I - N	lon-Deriva	ative	Securities Ac	quire	ed, D	isposed of	f, or Be	eneficia	lly Owned			
1. Title of Security (Instr. 3)  2. Tr Date (Mor				on Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities A Disposed Of (	(D) (Instr.	(A) or 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stock			09/27/20	06		Х		480	A	\$7.81	480	I	Sanderling II Limited Partnership	
Common Stock			09/27/20	06		F		358(1)	D	\$10.49	122	I	Sanderling II Limited Partnership	
Common Stock			09/27/20	06		X		16,805	A	<b>\$</b> 7.81	106,639	I	Sanderling V Beteiligungs GmbH & Co. KG	
Common Stock			09/27/20	06		х		4,332	A	<b>\$7.8</b> 1	110,971	I	Sanderling V Beteiligungs GmbH & Co. KG	
Common Stock			09/27/20	06		x		4,800	A	\$7.81	379,113	I	Sanderling V Biomedical Co- Investment Fund, L.P.	
Common Stock			09/27/20	06		х		18,051	A	\$7.81	397,164	I	Sanderling V Biomedical Co- Investment Fund, L.P.	
Common Stock			09/27/20	06		х		13,728	A	\$7.81	114,698	I	Sanderling V Limited Partnership	
Common Stock			09/27/20	06		X		4,868	A	\$7.81	119,566	I	Sanderling V Limited Partnership	
Common Stock			09/27/20	06		х		30,721	A	\$7.81	648,132	I	Sanderling Venture Partners V Co- Investment Fund, L.P.	

Table I - I	Non-Derivative	Securities A			isposed of	, or Be	eneficiall	y Owned		
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	09/27/2006		х		29,774	A	\$7.81	677,906	I	Sanderling Venture Partners V Co- Investment Fund, L.P.
Common Stock	09/27/2006		х		667	A	\$7.81	667	I	Sanderling Ventures Management V
Common Stock	09/27/2006		х		575	A	\$7.81	1,242	I	Sanderling Ventures Management V
Common Stock	09/27/2006		x		153,209	A	\$6.527	153,209	I	Sanderling Venture Partners VI Co- Investment Fund
Common Stock	09/27/2006		J <sup>(2)</sup>		7,703	D	\$0	145,506	I	Sanderling Venture Partners VI Co- Investment Fund
Common Stock	09/27/2006		J <sup>(2)</sup>		2,816	A	\$0	2,816	I	Sanderling VI Beteilgungs GmbH & Co. KG
Common Stock	09/27/2006		J <sup>(2)</sup>		3,355	A	\$0	3,355	I	Sanderling VI Limited Partnership
Common Stock	09/27/2006		J <sup>(2)</sup>		1,532	A	\$0	1,532	I	Sanderling Ventures Management VI
Common Stock								149,586	D	
Common Stock								15,000	I	Sanderling Mgmt. LLC 401K Pension Profit Sharing Plan
Common Stock								781,351	I	Sanderling Venture Partners II, L.P.
Common Stock								301,745	I	Sanderling Management Limited, FBO Sanderling Ventures Limited
Common Stock								532,758	I	Sanderling IV Biomedical Co- Investment Fund, L.P.

1. Title of Security (Instr. 3)					2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securitie Disposed C			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
							,,	8) Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		() (insura)		(Instr. 4)		
Common	ı Stock	I - Derivative S			Securities Acc		uirad Dis		snosed of	f. or Ber	eficially	224,515		I		Sanderling Venture Partners IV Co- Investment Fund, L.P.			
		la =		(e.g	., put	s, ca	ılls, ı	warrant	s, opti	ions	, convert	ible sec	urities)		I		I		
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	Execution if any	A. Deemed xecution Date, any Ionth/Day/Year)		4. Transaction Code (Instr. 8)				Exerc ion Da /Day/\		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	deriva Securi Benefi Owned Follow Report	ities icially d ving ted	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A) (D)		Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Series D-1 Common Stock Warrant	\$7.81	09/27/2006			х			480	11/21/2001		11/21/2006	Common Stock	480	\$0	0		I	Sanderling Limited Partnership	
Series D-1 Common Stock Warrant	\$7.81	09/27/2006			X			16,805	11/21/2	2001	11/21/2006	Common Stock	16,805	\$0	0		I	Sanderling V Beteiligung GmbH & Co. KG	
Series D-1 Common Stock Warrant	\$7.81	09/27/2006			x			4,800	11/21/2	2001	11/21/2006	Common Stock	4,800	\$0	0		I	Sanderling V Biomedical Co- Investment Fund, L.P.	
Series D-1 Common Stock Warrant	\$7.81	09/27/2006			х			13,728	11/21/2	2001	11/21/2006	Common Stock	13,728	\$0	0		I	Sanderling V Limited Partnership	
Series D-1 Common Stock Warrant	\$7.81	09/27/2006			x			30,721	11/21/2	2001	11/21/2006	Common Stock	30,721	\$0	0		I	Sanderling Venture Partners V Co- Investment Fund, L.P.	
Series D-1 Common Stock Warrant	\$7.81	09/27/2006			X			667	11/21/2	2001	11/21/2006	Common Stock	667	\$0	0		I	Sanderling Ventures Manageme V	
Series D-2 Common Stock Warrant	\$7.81	09/27/2006			X			4,332	12/17/2	2002	12/31/2007	Common Stock	4,332	\$0		0	I	Sanderling V Beteiligung GmbH & Co. KG	
Series D-2 Common Stock Warrant	\$7.81	09/27/2006			x			18,051	12/17/2	2002	12/31/2007	Common Stock	18,051	\$0	0		I	Sanderling V Biomedica Co- Investment Fund, L.P.	
Series D-2 Common Stock Warrant	\$7.81	09/27/2006			X			4,868	12/17/2	2002	12/31/2007	Common Stock	4,868	\$0		0	I	Sanderling V Limited Partnership	
Series D-2 Common Stock Warrant	\$7.81	09/27/2006			х			29,774	12/17/2	2002	12/31/2007	Common Stock	29,774	\$0	0		I	Sanderling Venture Partners V Co- Investment Fund, L.P.	
Series D-2 Common Stock Warrant	\$7.81	09/27/2006			X			575	12/17/2	2002	12/31/2007	Common Stock	575	\$0		0	I	Sanderling Ventures Manageme V	
	1	1	1				_	1	İ		<del>                                     </del>	1	1	1			1		

## Explanation of Responses:

\$6.527

1. Payment of warrant exercise price by delivering securities.

09/27/2006

2. Immediately upon exercise of the common stock warrant representing 153,209 shares of common stock, 7,703 shares were transferred to related entities as described on this Form 4.

153,209

(3)

X

3. Immediately.

Common Stock Warrant

Common Stock

11/28/2010

0

Sanderling

Venture Partners VI Co-Investment Fund, L.P.

I

153,209

\$<mark>0</mark>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.